In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Liquidia Technologies Inc (LQDA), with a price target of $49. The company’s shares closed yesterday at $10.84, close to its 52-week low of $10.50.
According to TipRanks.com, Moussatos has 0 stars on 0-5 star ranking scale with an average return of -8.4% and a 35.6% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Aquestive Therapeutics Inc, and Catabasis Pharmaceuticals.
Currently, the analyst consensus on Liquidia Technologies Inc is a Moderate Buy with an average price target of $49.
See today’s analyst top recommended stocks >>
The company has a one-year high of $38.46 and a one-year low of $10.50. Currently, Liquidia Technologies Inc has an average volume of 72.31K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing.
